In 2013, a first‐generation BTK inhibitor, ibrutinib, was first approved by the US FDA for mantle cell lymphoma (MCL), CLL/SLL with or without 17p deletion, waldenström's macroglobulinemia (WM), and MZL.421. This evidence concerns the gene BTK and mantle cell lymphoma.